Noninvasive indices of fibrosis in NAFLD

Starting to think about a three-hit (at least) phenomenon

Michael Charlton

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

NAFLD is a highly prevalent, phenotypically diverse condition. A small minority of patients with NAFLD progress to clinically important stages of fibrosis. Identifying patients at risk for progressive disease is one of the great challenges of hepatology. There are an increasing number of models that have been reported to provide noninvasive indices of histological severity of NAFLD, including a new report by Gholam et al. in this issue of the Journal. All models estimating risk of severity of NAFLD lack predictivity for future progression of fibrosis. Although conceptually considered to be a "two-hit" phenomenon, the combination of steatosis, necroinflammation, and progressive fibrosis is likely to be much more complex. Because the phenotypic expression of NAFLD, like so many liver diseases, is an interaction among genes, behavior, and environment, predicting future outcomes for patients with NAFLD (and liver diseases in general) will likely require models that combine genetic susceptibility, biological environment, and behavior. Emerging data are reviewed that suggest that it will not be long before studies like that of Gholam et al. are combined with those of clinical genomics to deliver tools that we can apply to the individual patient.

Original languageEnglish (US)
Pages (from-to)409-411
Number of pages3
JournalAmerican Journal of Gastroenterology
Volume102
Issue number2
DOIs
StatePublished - Feb 2007

Fingerprint

Fibrosis
Liver Diseases
Gastroenterology
Genetic Predisposition to Disease
Genomics
Non-alcoholic Fatty Liver Disease
Genes

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Noninvasive indices of fibrosis in NAFLD : Starting to think about a three-hit (at least) phenomenon. / Charlton, Michael.

In: American Journal of Gastroenterology, Vol. 102, No. 2, 02.2007, p. 409-411.

Research output: Contribution to journalArticle

@article{710b1992a03b406f8b127aa841baba7c,
title = "Noninvasive indices of fibrosis in NAFLD: Starting to think about a three-hit (at least) phenomenon",
abstract = "NAFLD is a highly prevalent, phenotypically diverse condition. A small minority of patients with NAFLD progress to clinically important stages of fibrosis. Identifying patients at risk for progressive disease is one of the great challenges of hepatology. There are an increasing number of models that have been reported to provide noninvasive indices of histological severity of NAFLD, including a new report by Gholam et al. in this issue of the Journal. All models estimating risk of severity of NAFLD lack predictivity for future progression of fibrosis. Although conceptually considered to be a {"}two-hit{"} phenomenon, the combination of steatosis, necroinflammation, and progressive fibrosis is likely to be much more complex. Because the phenotypic expression of NAFLD, like so many liver diseases, is an interaction among genes, behavior, and environment, predicting future outcomes for patients with NAFLD (and liver diseases in general) will likely require models that combine genetic susceptibility, biological environment, and behavior. Emerging data are reviewed that suggest that it will not be long before studies like that of Gholam et al. are combined with those of clinical genomics to deliver tools that we can apply to the individual patient.",
author = "Michael Charlton",
year = "2007",
month = "2",
doi = "10.1111/j.1572-0241.2006.01039.x",
language = "English (US)",
volume = "102",
pages = "409--411",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Noninvasive indices of fibrosis in NAFLD

T2 - Starting to think about a three-hit (at least) phenomenon

AU - Charlton, Michael

PY - 2007/2

Y1 - 2007/2

N2 - NAFLD is a highly prevalent, phenotypically diverse condition. A small minority of patients with NAFLD progress to clinically important stages of fibrosis. Identifying patients at risk for progressive disease is one of the great challenges of hepatology. There are an increasing number of models that have been reported to provide noninvasive indices of histological severity of NAFLD, including a new report by Gholam et al. in this issue of the Journal. All models estimating risk of severity of NAFLD lack predictivity for future progression of fibrosis. Although conceptually considered to be a "two-hit" phenomenon, the combination of steatosis, necroinflammation, and progressive fibrosis is likely to be much more complex. Because the phenotypic expression of NAFLD, like so many liver diseases, is an interaction among genes, behavior, and environment, predicting future outcomes for patients with NAFLD (and liver diseases in general) will likely require models that combine genetic susceptibility, biological environment, and behavior. Emerging data are reviewed that suggest that it will not be long before studies like that of Gholam et al. are combined with those of clinical genomics to deliver tools that we can apply to the individual patient.

AB - NAFLD is a highly prevalent, phenotypically diverse condition. A small minority of patients with NAFLD progress to clinically important stages of fibrosis. Identifying patients at risk for progressive disease is one of the great challenges of hepatology. There are an increasing number of models that have been reported to provide noninvasive indices of histological severity of NAFLD, including a new report by Gholam et al. in this issue of the Journal. All models estimating risk of severity of NAFLD lack predictivity for future progression of fibrosis. Although conceptually considered to be a "two-hit" phenomenon, the combination of steatosis, necroinflammation, and progressive fibrosis is likely to be much more complex. Because the phenotypic expression of NAFLD, like so many liver diseases, is an interaction among genes, behavior, and environment, predicting future outcomes for patients with NAFLD (and liver diseases in general) will likely require models that combine genetic susceptibility, biological environment, and behavior. Emerging data are reviewed that suggest that it will not be long before studies like that of Gholam et al. are combined with those of clinical genomics to deliver tools that we can apply to the individual patient.

UR - http://www.scopus.com/inward/record.url?scp=33846529926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846529926&partnerID=8YFLogxK

U2 - 10.1111/j.1572-0241.2006.01039.x

DO - 10.1111/j.1572-0241.2006.01039.x

M3 - Article

VL - 102

SP - 409

EP - 411

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 2

ER -